Abstract: An aerodynamic device includes a main aerodynamic body having a leading edge and a trailing edge, a flight control surface coupled to the main aerodynamic body near the trailing edge of the main aerodynamic body, and a rotating body coupled to the flight control surface. The rotating body is rotatable relative to the flight control surface between a stowed position and a deployed position to define a gap. The rotating body is rotated toward the main aerodynamic body while in the stowed position to close the gap. The rotating body is rotated away from the main aerodynamic body while in the deployed position to widen the gap. The gap adjusts an airflow flowing between the main aerodynamic body and the flight control surface.

Abstract: An aerodynamic device includes a main aerodynamic body having a leading edge and a trailing edge, a flight control surface coupled to the main aerodynamic body near the trailing edge of the main aerodynamic body, and a translating body coupled to the flight control surface. The translating body is moveable relative to the flight control surface between a sealed position and a retracted position to define a gap. The translating body is extended toward the main aerodynamic body while in the sealed position to close the gap. The translating body is retracted away from the main aerodynamic body while in the retracted position to widen the gap. The gap adjusts an airflow flowing between the main aerodynamic body and the flight control surface.

Abstract: An aerodynamic device includes a main aerodynamic body having a leading edge and a trailing edge, a flight control surface coupled to the main aerodynamic body near the trailing edge of the main aerodynamic body, and a rotating body coupled to the flight control surface. The rotating body is rotatable relative to the flight control surface between a stowed position and a deployed position to define a gap. The rotating body is rotated toward the main aerodynamic body while in the stowed position to close the gap. The rotating body is rotated away from the main aerodynamic body while in the deployed position to widen the gap. The gap adjusts an airflow flowing between the main aerodynamic body and the flight control surface.

Abstract: An aerodynamic device includes a main aerodynamic body having a leading edge and a trailing edge, a flight control surface coupled to the main aerodynamic body near the trailing edge of the main aerodynamic body, and a translating body coupled to the flight control surface. The translating body is moveable relative to the flight control surface between a sealed position and a retracted position to define a gap. The translating body is extended toward the main aerodynamic body while in the sealed position to close the gap. The translating body is retracted away from the main aerodynamic body while in the retracted position to widen the gap. The gap adjusts an airflow flowing between the main aerodynamic body and the flight control surface.

Abstract: An aircraft comprises a wing assembly, a pod, and a pylon attaching the pod to the wing assembly. The pylon has a swept pylon flap, which is configured to unload the pylon and pod during flight of the aircraft, and also to create downward flow that counters a vortex trailing the pod.

Abstract: An aircraft comprises a wing assembly, a pod, and a pylon attaching the pod to the wing assembly. The pylon has a swept pylon flap, which is configured to unload the pylon and pod during flight of the aircraft, and also to create downward flow that counters a vortex trailing the pod.

Abstract: Methods for financing dealer debt instruments for customers of a dealer are disclosed. One method, among others, an underwriter system that finances a dealer debt instrument based upon at least one of customer information, product information, and transaction information for the dealer debt instrument. The underwriter system may calculate an initial purchase offer, and then adjust the initial purchase offer based at least upon at least one of product information and transaction information. In some situations, the underwriter system may provide a dealer with multiple purchase offers for one debt instrument.

Abstract: Methods for financing dealer debt instruments for customers of a dealer are disclosed. One method, among others, an underwriter system that finances a dealer debt instrument based upon at least one of customer information, product information, and transaction information for the dealer debt instrument. The underwriter system may calculate an initial purchase offer, and then adjust the initial purchase offer based at least upon at least one of product information and transaction information. In some situations, the underwriter system may provide a dealer with multiple purchase offers for one debt instrument.

Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.

Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.

Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.

Abstract: A calculator front-end to a deal financing system that enables a dealer to enter parameters regarding the pending transaction and calculate the values of an advance needed to break even and/or attain a profit goal.

Abstract: Methods for financing dealer debt instruments for customers of a dealer are disclosed. One method, among others, an underwriter system that finances a dealer debt instrument based upon at least one of customer information, product information, and transaction information for the dealer debt instrument. The underwriter system may calculate an initial purchase offer, and then adjust the initial purchase offer based at least upon at least one of product information and transaction information. In some situations, the underwriter system may provide a dealer with multiple purchase offers for one debt instrument.

Abstract: Methods for providing payment codes to borrowers are disclosed. One method, among others, includes providing payment codes through at least one self-service channel. The borrowers may retrieve their payment codes through the at least one self-service channel without the assistance of another person.

Abstract: A vaginal discharge collection device is formed of an elastomeric rim and a flexible film reservoir. The rim may have a generally rectangular cross section and forms a collection space for collecting vaginal discharge. The reservoir may be collapsible so as to be substantially enclosed within the rim when the device is being used. Advantageously, the rim and the reservoir are arranged such that compressing diametrically opposed portions of the rim toward each other causes a leading portion of the rim to dip downwardly to facilitate insertion of the device. The device is ergonomically constructed so as to be convenient to use, comfortable to wear internally, and reliable. A system for reliably, comfortably and conveniently introducing agents, including drugs and other substances, into the vaginal canal is also disclosed.

Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori! can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.

Abstract: An entirely aqueous method for concentrating beta-glucan from a beta-glucan source, such as milled cereal bran, grain or distiller's dried grain. The method comprises providing an alkaline aqueous extract of a beta-glucan source; acidifying or neutralizing the extract and heating the extract to between about 60° C. and 100° C.; cooling the extract, whereby a flocculate is formed; acidifying the cooled extract if the extract was neutralized; and removing the flocculate from the aqueous solution to form an intermediate solution. The intermediate solution may be subjected to ultrafiltration for further purification of beta-glucan, or may be evaporated, resulting in formation of a solid film enriched in beta-glucan. Beta-glucan has cholesterol-lowering properties and is a topical immunostimulant.

Abstract: An entirely aqueous method for concentrating beta-glucan from a beta-glucan source, such as milled cereal bran, grain or distiller's dried grain. The method comprises providing an alkaline aqueous extract of a beta-glucan source; acidifying or neutralizing the extract and heating the extract to between about 60° C. and 100° C.; cooling the extract, whereby a flocculate is formed; acidifying the cooled extract if the extract was neutralized; and removing the flocculate from the aqueous solution to form an intermediate solution. The intermediate solution may be subjected to ultrafiltration for further purification of beta-glucan, or may be evaporated, resulting in formation of a solid film enriched in beta-glucan. Beta-glucan has cholesterol-lowering properties and is a topical immunostimulant.

Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispersed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.

Abstract: Diseases and disorders of dermal tissue such as the skin, hair and nails are treated or prevented by administering one or more lectins, capable of binding to the surface of pathogenic microorganisms inhabiting the hair, skin, and nails, or of binding to the superficial tissues that comprise hair, skin, and nails. The lectins may be administered topically or subcutaneously to a patient infected with pathogenic microorganisms or in danger of being exposed to such pathogens. Lectins that stimulate cell mitosis may also be administered to accelerate wound healing and restore the appearance of age-wrinkled skin. Lectins that coagulate blood can be administered to assist in stopping bleeding from skin lesions. The lectins may be applied to the skin in a pharmceutically acceptable vehicle.